Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of autoimmune diseases, including AIDS

Inactive Publication Date: 2005-08-11
ADVANCED BIOTHERAPY
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a method of treating autoimmune diseases by blocking, inhibiting, or removing harmful interferons, tumor necrosis factors, and other pathological immunogens or factors. The method involves administering to a patient an effective amount of anti-IFNγ antibodies and / or antibodies to IFNγ receptor, anti-TNF antibodies and antibodies to TNF receptor, and antibodies to an HLA class II antigen or its receptor. The invention also provides a method of extracorporeal treatment by removing antigens from the patient by drawing fluid from the patient and passing it through an immunosorbent comprising a combination of antibodies. The invention can be used to treat specific autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

Problems solved by technology

However, because autoimmune diseases are complex, often characterized by multiple cytokine abnormalities, effective treatment appears to require the simultaneous administration or utilization of several agents, each targeting a specific cytokine pathway or its by-product.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of the Immunosorbent Column

[0105] Using a column and tubing made of plastic approved for the use of blood, a column is prepared of small total volume, approximately 30-35 ml. The column is filled with immunosorbent, consisting essentially of one or more antigens or antibodies bound to Sepharose 4B or another suitable matrix, through a short filling tube placed at one end of the column. After the column has been filled, an input tube to introduce the fluid sample, and a return tube to return the treated sample to its source, are connected to either end of the column. A filter is interposed between the input tube and the column, and a second filter is interposed between the column and the return tube. The two filters prevent the flow of immunosorbent from the column. Two way stopcocks on the tubes regulate flow throughout the system.

[0106] Sepharose CL-4B (Pharmacia, Piscattaway, N.J.) (100 ml) is washed thoroughly with pyrogen free water, then suspended in 0.300 ml ice ...

example 2

Production of Antibody to Human IFNγ

[0109] Adult rabbits are immunized with purified human IFNγ (105-106 unit / mg protein). The interferon is first mixed with equal volumes of Freund's Complete Adjuvant and 30% Arlacel A and injected IM or subcutaneously on day 1, 4, 14 and 43 (100 units, 200 units, 200, 200 respectively). Next, 200,000 units of the interferon is injected per month, for an additional 6 months. The serum is drawn from the rabbit when the titer has reached 100 units (1 unit of antibody neutralizes 10 units of gamma IFN), after which IgG is isolated and substantially purified in accordance with recognized methods.

example 3

Responses to TNFα IFNα and IFNγ Antibodies, Separately and Together, in Patients with Active Rheumatoid Arthritis and Ankylosing Spondylitis

[0110] Polyclonal antibodies were obtained by immunizing sheep with natural human IFNα, and goats with recombinant human IFNγ (“r-Hu-IFNγ”) or recombinant human TNFα (“r-Hu-TNFα”), and isolating the IgG from the animals. Each milliliter of IgG contained approximately 50 mg of protein, and the antibodies showed a 1:5 signal to noise ratio at 1:1250 (anti-IFNα antibodies) and 1:12,500 (anti-IFNγ antibodies and anti-TNFα antibodies) dilutions by ELISA (Cytolmmune Sciences, Inc.). After obtaining approval and informed consent, 20 human patients with very severe rheumatoid arthritis (“RA”), aged 27-64, average disease duration 9 years, were equally randomized to one of four (4) treatment groups. The patients in Group A, B and C were given one intramuscular administration of 2-3 ml / day for 5 consecutive days of (Group A) anti-TNFα antibodies; (Group ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
total volumeaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathological factors and / or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient; or it comprises a combined therapy involving extracorporeal immunosorption in conjunction with the administration of an autoimmune inhibitor.

Description

BACKGROUND OF THE INVENTION [0001] This application is a continuation-in-part of U.S. application Ser. No. 08 / 025,408, filed Feb. 26, 1993.FIELD OF INVENTION [0002] The present invention is a method to treat autoimmune diseases and conditions in a patient, which are caused by the disturbance of the synthesis of interferons (IFNs) and certain other substances (e.g., tumor necrosis factors (TNFs)) and the production of autoantibodies to target cells, including CD4 cells, which damage the patient's immune system and have a direct pathological action on the patient's cells. DESCRIPTION OF RELATED ART [0003] The ability of the immune system to discriminate between “self” and “non-self” antigens is vital to the functioning of the immune system as a specific defense against invading microorganisms. “Non-self” antigens are those antigens on substances entering or in the body which are detectably different or foreign from the animal's own constituents, whereas “self” antigens are those which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/00A61K39/395C07K16/24C07K16/28
CPCA61K38/00A61K39/395C07K16/241C07K16/249C07K16/2833A61K2300/00
Inventor SKURKOVICH, BORISSKURKOVICH, SIMON V.
Owner ADVANCED BIOTHERAPY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com